Pay in 4 interest-free payments of $7.04 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
has happened: its pivotal Phase 3 obesity trial, TRIUMPH-1, reported topline results on May 21, 2026 (28.3% average weight loss at 80 weeks) and is now marked complete on ClinicalTrials.gov, followed by TRIUMPH-2 and TRIUMPH-3 on July 23, 2026
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial
A small pilot study in athletes found more consistent blood levels when oral doses were taken in a fasted state versus with dinner in the evening
At ReverseAll, we help patients navigate this transition with science-backed, personalised care focused on long-term metabolic health
US$ 29.48
US$ 23.93
US$ 27.50
US$ 29.24
